JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 µM, Kd=0.42 µM), targets REV1 that interacts with the REV7 subunit of POLzeta. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLzeta. JH-RE-06 improves chemotherapy[1][2].
Molecular Weight:
468.72
Purity:
99.87
CAS Number:
[1361227-90-8]
Formula:
C20H16Cl3N3O4
Target:
DNA/RNA Synthesis
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
